Relapse of imported vivax malaria despite standard-dose primaquine therapy: An investigation with molecular genotyping analyses

Clinical Microbiology and Infection

Volumn 18, Issue 7, 2012, Pages

  Chiang, T Y ^a,b   Lin, W C ^a   Kuo, M C ^a   Ji, D D ^a,c,e   Fang, C T ^b,d  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Indonesia; Plasmodium vivax malaria; Primaquine; Relapse; Solomon Islands

Indexed keywords

PRIMAQUINE;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENETIC ANALYSIS; HUMAN; INDONESIA; MALARIA CONTROL; MALE; MOLECULAR GENETICS; PACIFIC ISLANDS; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RELAPSE; SOLOMON ISLANDS; SOUTHEAST ASIA; TAIWAN;

PLASMODIUM VIVAX;

EID: 84862618379     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03820.x     Document Type: Article

References (19)

1. Spudick JM, Garcia LS, Graham DM, Haake DA. Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. J Clin Microbiol 2005; 43: 978-981.
2. Bottieau E, Clerinx J, Van Den Enden E et al. Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center. Am J Trop Med Hyg 2006; 75: 133-138.
3. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009; 22: 508-534.
4. Krotoski WA. Frequency of relapse and primaquine resistance in Southeast Asian vivax malaria. N Engl J Med 1980; 303: 587.
5. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39: 1336-1345.
6. Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States (based on drugs currently available for use in the United States - updated September 23, 2011). Available at: Accessed 15 February, 2012.
7. World Health Organization. Guidelines for the treatment of malaria. Geneva, Switzerland: World Health Organization, 2010.
8. Fang CT, Chang HL, Hsieh WC. Malaria eradication on islands. Lancet 2001; 357: 560.
9. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol 1993; 58: 283-292.
10. Zakeri S, Motmaen SR, Afsharpad M, Djadid ND. Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Malar J 2009; 8: 20.
11. Marfurt J, de Monbrison F, Brega S et al. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis 2008; 198: 409-417.
12. Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G. Genetic structure of Plasmodium vivax and Plasmodium falciparum in the Bannu district of Pakistan. Malar J 2010; 9: 112.
13. Yang Z, Miao J, Huang Y et al. Genetic structures of geographically distinct Plasmodium vivax populations assessed by PCR/RFLP analysis of the merozoite surface protein 3beta gene. Acta Trop 2006; 100: 205-212.
14. World Health Organization. Global database on body mass index. Available at: Accessed 15 February, 2012.
15. Santos JB, Luz FC, Deckers FA, Tauil PL. Subdoses of primaquine in overweight patients and malaria vivax relapses: report of two cases in the Federal District, Brazil. Rev Soc Bras Med Trop 2010; 43: 749-750.
16. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 2001; 65: 471-476.
17. Krudsood S, Tangpukdee N, Wilairatana P et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 2008; 78: 736-740.
18. Imwong M, Snounou G, Pukrittayakamee S et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007; 195: 927-933.
19. Koepfli C, Mueller I, Marfurt J et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 2009; 199: 1074-1080.